{"transactions":[{"id":4615575,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:03.000Z","date":"2026-09-10","kind":"purchase","planned":false,"acquired":true,"shares":79800,"price":4.25,"value":339150.0,"ownership":{"direct":true},"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-26-098970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390026098970/ownership.xml","form_type":"4"}},{"id":4615574,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:03.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":120200,"price":4.2,"value":504840.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $4.16 to $4.20 per share, inclusive."}],"balance_after":920200,"source":{"system":"sec-edgar","filing":"0001213900-26-098970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390026098970/ownership.xml","form_type":"4"}},{"id":967575,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T09:30:24.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":828000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":828000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":828000},"source":{"system":"sec-edgar","filing":"0001213900-25-121973","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025121973/ownership.xml","form_type":"4"}},{"id":967574,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T09:30:24.000Z","date":"2025-12-15","kind":"purchase","planned":false,"acquired":true,"shares":11665,"price":4.12,"value":48059.8,"ownership":{"direct":true},"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001213900-25-121973","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025121973/ownership.xml","form_type":"4"}},{"id":1005798,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-06T07:30:07.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":2.2,"value":1100000.0,"ownership":{"direct":true},"balance_after":788335,"source":{"system":"sec-edgar","filing":"0001213900-25-106836","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025106836/ownership.xml","form_type":"4"}},{"id":1099248,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T19:29:01.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":600000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001213900-25-059869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025059869/ownership.xml","form_type":"4"}},{"id":1140430,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:12.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":0.5237,"value":31422.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $0.4998 to $0.5396 per share, inclusive."}],"balance_after":288335,"source":{"system":"sec-edgar","filing":"0001213900-25-046087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025046087/ownership.xml","form_type":"4"}},{"id":1140429,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:12.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":90000,"price":0.4854,"value":43686.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $0.4493 to $0.4998 per share, inclusive."}],"balance_after":228335,"source":{"system":"sec-edgar","filing":"0001213900-25-046087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025046087/ownership.xml","form_type":"4"}},{"id":1140428,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:12.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.442,"value":22100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.4229 to $0.4674 per share, inclusive."}],"balance_after":138335,"source":{"system":"sec-edgar","filing":"0001213900-25-046087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025046087/ownership.xml","form_type":"4"}},{"id":1409759,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-11T17:46:42.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":24120,"price":2.95,"value":71154.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $2.79 to $3.05 per share, inclusive."}],"balance_after":88335,"source":{"system":"sec-edgar","filing":"0001213900-24-077792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024077792/ownership.xml","form_type":"4"}},{"id":1409758,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-11T17:46:42.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":21118,"price":2.73,"value":57652.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $2.70 to $2.75 per share, inclusive."}],"balance_after":64215,"source":{"system":"sec-edgar","filing":"0001213900-24-077792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024077792/ownership.xml","form_type":"4"}},{"id":1409757,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-11T17:46:42.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":8194,"price":2.55,"value":20894.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $2.49 to $2.60 per share, inclusive."}],"balance_after":43097,"source":{"system":"sec-edgar","filing":"0001213900-24-077792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024077792/ownership.xml","form_type":"4"}},{"id":1499141,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:24:53.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":54624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":82090,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":54624},"source":{"system":"sec-edgar","filing":"0001213900-24-047638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024047638/ownership.xml","form_type":"4"}},{"id":1499140,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:24:53.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":54624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":136714,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":54624},"source":{"system":"sec-edgar","filing":"0001213900-24-047638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024047638/ownership.xml","form_type":"4"}},{"id":1665178,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-31T18:28:58.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":6875,"price":4.0645,"value":27943.4375,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $3.95 to $4.18 per share, inclusive."}],"balance_after":34903,"source":{"system":"sec-edgar","filing":"0001213900-24-008559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024008559/ownership.xml","form_type":"4"}},{"id":1665177,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-31T18:28:58.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":3.8882,"value":58323.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $3.82 to $3.90 per share, inclusive."}],"balance_after":28028,"source":{"system":"sec-edgar","filing":"0001213900-24-008559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024008559/ownership.xml","form_type":"4"}},{"id":1665176,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-31T18:28:58.000Z","date":"2024-01-29","kind":"purchase","planned":false,"acquired":true,"shares":10800,"price":3.6528,"value":39450.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $3.57 to $3.745 per share, inclusive."}],"balance_after":13028,"source":{"system":"sec-edgar","filing":"0001213900-24-008559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024008559/ownership.xml","form_type":"4"}},{"id":1704874,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T17:28:31.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":82090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":82090,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":82090},"source":{"system":"sec-edgar","filing":"0001213900-23-097031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390023097031/ownership.xml","form_type":"4"}},{"id":1874846,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T17:09:53.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":317643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":512560,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":317643},"source":{"system":"sec-edgar","filing":"0001213900-23-044089","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390023044089/ownership.xml","form_type":"4"}},{"id":2079795,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-20T19:31:02.000Z","date":"2022-12-16","kind":"other","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Not applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Original expiration date."}],"balance_after":0,"derivative":{"exercise_price":19.03,"expiration_date":"2031-12-17","underlying":"Common stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-22-081519","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390022081519/ownership.xml","form_type":"4"}},{"id":2079794,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-20T17:34:03.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":194917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"62,560 of the shares are immediately vested; 132,357 shares vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":194917,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":194917},"source":{"system":"sec-edgar","filing":"0001213900-22-081479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390022081479/ownership.xml","form_type":"4"}},{"id":2255259,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T18:42:56.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the \"Plan\") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder (\"MDD\") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol."}],"balance_after":200000,"derivative":{"exercise_price":19.03,"expiration_date":"2031-12-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-22-029837","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390022029837/ownership.xml","form_type":"4"}},{"id":2255258,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T18:42:56.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":295211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the \"Plan\") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022."}],"balance_after":522729,"derivative":{"exercise_price":19.03,"exercise_date":"2022-03-17","expiration_date":"2031-12-17","underlying":"Common Stock","underlying_shares":295211},"source":{"system":"sec-edgar","filing":"0001213900-22-029837","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390022029837/ownership.xml","form_type":"4"}},{"id":2462447,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-21T21:30:52.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":227518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 equal quarterly installments commencing on March 17, 2022."}],"balance_after":227518,"derivative":{"exercise_price":19.03,"exercise_date":"2022-03-17","expiration_date":"2031-12-17","underlying":"Common Stock","underlying_shares":227518},"source":{"system":"sec-edgar","filing":"0001213900-21-066822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021066822/ownership.xml","form_type":"4"}},{"id":2797025,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-03-10T18:18:21.000Z","date":"2021-03-08","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":70350,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-21-014656","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021014656/ownership.xml","form_type":"4"}},{"id":2797024,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-03-10T18:18:21.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":2373,"price":35.1089,"value":83313.4197,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.00 to $35.37 per share, inclusive."}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-014656","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021014656/ownership.xml","form_type":"4"}},{"id":2797023,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-03-10T18:18:21.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":1800,"price":36.02,"value":64836.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $36.02 to $36.51 per share, inclusive."}],"balance_after":4601,"source":{"system":"sec-edgar","filing":"0001213900-21-014656","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021014656/ownership.xml","form_type":"4"}},{"id":2797022,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-03-10T18:18:21.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":5727,"price":35.4212,"value":202857.2124,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.02 to $35.95 per share, inclusive."}],"balance_after":6401,"source":{"system":"sec-edgar","filing":"0001213900-21-014656","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021014656/ownership.xml","form_type":"4"}},{"id":2797021,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-03-10T18:18:21.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":100,"price":35,"value":3500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."}],"balance_after":12128,"source":{"system":"sec-edgar","filing":"0001213900-21-014656","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021014656/ownership.xml","form_type":"4"}},{"id":2797020,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-03-10T18:18:21.000Z","date":"2021-03-08","kind":"exercise","acquired":true,"shares":10000,"price":3.24,"value":32400.0,"ownership":{"direct":true},"balance_after":12228,"source":{"system":"sec-edgar","filing":"0001213900-21-014656","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021014656/ownership.xml","form_type":"4"}},{"id":2829727,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-02-26T16:48:23.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":80250,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001213900-21-012169","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021012169/ownership.xml","form_type":"4"}},{"id":2829726,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-26T16:48:23.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":1400,"price":34.6746,"value":48544.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $34.47 to $35.03 per share, inclusive."}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-012169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021012169/ownership.xml","form_type":"4"}},{"id":2829725,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-26T16:48:23.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":1600,"price":33.7405,"value":53984.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $33.35 to $34.30 per share, inclusive."}],"balance_after":3628,"source":{"system":"sec-edgar","filing":"0001213900-21-012169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021012169/ownership.xml","form_type":"4"}},{"id":2829724,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-26T16:48:23.000Z","date":"2021-02-24","kind":"exercise","acquired":true,"shares":3000,"price":3.24,"value":9720.0,"ownership":{"direct":true},"balance_after":5228,"source":{"system":"sec-edgar","filing":"0001213900-21-012169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021012169/ownership.xml","form_type":"4"}},{"id":2859109,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-02-16T17:08:47.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":1428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":83250,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":1428},"source":{"system":"sec-edgar","filing":"0001213900-21-009696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021009696/ownership.xml","form_type":"4"}},{"id":2859108,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-16T17:08:47.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":1428,"price":35.3936,"value":50542.0608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.12 to $35.96 per share, inclusive."}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-009696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021009696/ownership.xml","form_type":"4"}},{"id":2859107,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-16T17:08:47.000Z","date":"2021-02-11","kind":"exercise","acquired":true,"shares":1428,"price":3.24,"value":4626.72,"ownership":{"direct":true},"balance_after":3656,"source":{"system":"sec-edgar","filing":"0001213900-21-009696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021009696/ownership.xml","form_type":"4"}},{"id":2869230,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-02-10T19:25:15.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":11372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":84678,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":11372},"source":{"system":"sec-edgar","filing":"0001213900-21-008202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021008202/ownership.xml","form_type":"4"}},{"id":2869229,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-10T19:25:15.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":2410,"price":35.1973,"value":84825.493,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.00 to $35.64 per share, inclusive"}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-008202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021008202/ownership.xml","form_type":"4"}},{"id":2869228,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-10T19:25:15.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":5359,"price":35.2385,"value":188843.1215,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $35.00 to $35.82 per share, inclusive"}],"balance_after":4638,"source":{"system":"sec-edgar","filing":"0001213900-21-008202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021008202/ownership.xml","form_type":"4"}},{"id":2869227,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-10T19:25:15.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":3603,"price":35.0379,"value":126241.5537,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.00 to $35.29 per share, inclusive."}],"balance_after":9997,"source":{"system":"sec-edgar","filing":"0001213900-21-008202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021008202/ownership.xml","form_type":"4"}},{"id":2869226,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-10T19:25:15.000Z","date":"2021-02-08","kind":"exercise","acquired":true,"shares":11372,"price":3.24,"value":36845.28,"ownership":{"direct":true},"balance_after":13600,"source":{"system":"sec-edgar","filing":"0001213900-21-008202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021008202/ownership.xml","form_type":"4"}},{"id":2879213,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-02-04T17:38:39.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":96050,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001213900-21-006832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021006832/ownership.xml","form_type":"4"}},{"id":2879212,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-04T17:38:39.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":100,"price":35,"value":3500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-006832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021006832/ownership.xml","form_type":"4"}},{"id":2879211,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-04T17:38:39.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":3100,"price":35.0432,"value":108633.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.00 to $35.21 per share, inclusive."}],"balance_after":2328,"source":{"system":"sec-edgar","filing":"0001213900-21-006832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021006832/ownership.xml","form_type":"4"}},{"id":2879210,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-02-04T17:38:39.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":3200,"price":3.24,"value":10368.0,"ownership":{"direct":true},"balance_after":5428,"source":{"system":"sec-edgar","filing":"0001213900-21-006832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021006832/ownership.xml","form_type":"4"}},{"id":2890344,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-01-29T17:24:03.000Z","date":"2021-01-27","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":99250,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001213900-21-005451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021005451/ownership.xml","form_type":"4"}},{"id":2890343,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-29T17:24:03.000Z","date":"2021-01-27","kind":"sale","acquired":false,"shares":1200,"price":32.43,"value":38916.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $32.66 to $33.43 per share, inclusive."}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-005451","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021005451/ownership.xml","form_type":"4"}},{"id":2890342,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-29T17:24:03.000Z","date":"2021-01-27","kind":"sale","acquired":false,"shares":1800,"price":31.59,"value":56862.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $31.59 to $32.50 per share, inclusive."}],"balance_after":3428,"source":{"system":"sec-edgar","filing":"0001213900-21-005451","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021005451/ownership.xml","form_type":"4"}},{"id":2890341,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-29T17:24:03.000Z","date":"2021-01-27","kind":"exercise","acquired":true,"shares":3000,"price":3.24,"value":9720.0,"ownership":{"direct":true},"balance_after":5228,"source":{"system":"sec-edgar","filing":"0001213900-21-005451","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021005451/ownership.xml","form_type":"4"}},{"id":2893503,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-27T07:46:46.000Z","date":"2021-01-22","kind":"exercise","acquired":true,"shares":4000,"price":3.24,"value":12960.0,"ownership":{"direct":true},"balance_after":6228,"source":{"system":"sec-edgar","filing":"0001213900-21-004515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004515/ownership.xml","form_type":"4/A","original_submission_date":"2021-01-27"}},{"id":2895194,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-01-26T19:28:50.000Z","date":"2021-01-22","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":102250,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-21-004478","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004478/ownership.xml","form_type":"4"}},{"id":2895193,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-26T19:28:50.000Z","date":"2021-01-26","kind":"sale","acquired":false,"shares":607,"price":35.16,"value":21342.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sales prices range from $35.00 to $35.61 per share, inclusive."}],"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-21-004478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004478/ownership.xml","form_type":"4"}},{"id":2895192,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-26T19:28:50.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":1280,"price":35.27,"value":45145.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.00 to $35.51 per share, inclusive."}],"balance_after":2835,"source":{"system":"sec-edgar","filing":"0001213900-21-004478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004478/ownership.xml","form_type":"4"}},{"id":2895191,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-26T19:28:50.000Z","date":"2021-01-22","kind":"sale","acquired":false,"shares":409,"price":36.15,"value":14785.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $36.06 to $36.37 per share, inclusive."}],"balance_after":4115,"source":{"system":"sec-edgar","filing":"0001213900-21-004478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004478/ownership.xml","form_type":"4"}},{"id":2895190,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-26T19:28:50.000Z","date":"2021-01-22","kind":"sale","acquired":false,"shares":1704,"price":35.41,"value":60338.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.04 to $35.98 per share, inclusive."}],"balance_after":4524,"source":{"system":"sec-edgar","filing":"0001213900-21-004478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004478/ownership.xml","form_type":"4"}},{"id":2895189,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2021-01-26T19:28:50.000Z","date":"2021-01-22","kind":"exercise","acquired":true,"shares":4000,"price":324,"value":1296000.0,"ownership":{"direct":true},"balance_after":6228,"source":{"system":"sec-edgar","filing":"0001213900-21-004478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021004478/ownership.xml","form_type":"4"}},{"id":2911027,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-01-11T16:07:06.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 25% one year from the date of grant, and thereafter in equal quarterly increments of 6.25% over the following three years. The options are subject to forfeiture upon failure by the Issuer to reach certain corporate objectives in 2021."}],"balance_after":127500,"derivative":{"exercise_price":33.43,"exercise_date":"2022-01-07","expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-21-001419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021001419/ownership.xml","form_type":"4"}},{"id":2911026,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Options to purchase common stock","published_at":"2021-01-11T16:07:06.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period."}],"balance_after":127500,"derivative":{"exercise_price":33.43,"exercise_date":"2021-04-07","expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-21-001419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390021001419/ownership.xml","form_type":"4"}},{"id":3332630,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2019-12-23T16:51:44.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":120000,"price":43.47,"value":5216400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":120000,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001213900-19-026848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390019026848/ownership.xml","form_type":"4"}},{"id":3390153,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-21T16:23:29.000Z","date":"2019-10-21","kind":"purchase","acquired":true,"shares":978,"price":23,"value":22494.0,"ownership":{"direct":true},"balance_after":2228,"source":{"system":"sec-edgar","filing":"0001213900-19-020722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390019020722/ownership.xml","form_type":"4"}},{"id":3453271,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2019-07-30T17:09:32.000Z","date":"2019-07-29","kind":"grant","acquired":true,"shares":500000,"price":2.2,"value":1100000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":500000,"derivative":{"exercise_price":2.2,"expiration_date":"2029-07-29","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-19-014043","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390019014043/ownership.xml","form_type":"4"}},{"id":3713379,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2019-01-02T18:44:36.000Z","date":"2018-12-28","kind":"purchase","acquired":true,"shares":20000,"price":1.3107,"value":26214.0,"ownership":{"direct":true},"balance_after":62500,"source":{"system":"sec-edgar","filing":"0001415889-19-000015","document":"form4-01022019_030120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000141588919000015/form4-01022019_030120.xml","form_type":"4"}},{"id":3723355,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2018-12-20T16:55:17.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":450000,"price":1.15,"value":517500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":450000,"derivative":{"exercise_price":1.15,"expiration_date":"2028-12-20","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001213900-18-017635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390018017635/ownership.xml","form_type":"4"}},{"id":3867310,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Options","published_at":"2018-07-16T19:20:19.000Z","date":"2018-07-12","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options with respect to 50,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 50,000 shares vest upon the the first CF patient doses with MS1819 anywhere in the globe."}],"balance_after":100000,"derivative":{"exercise_price":3.04,"expiration_date":"2023-06-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-18-001118","document":"form4-07162018_040700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000141588918001118/form4-07162018_040700.xml","form_type":"4"}},{"id":4181888,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2017-10-23T17:43:02.000Z","date":"2017-10-19","kind":"grant","acquired":true,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarters ending March 31, 2017, June 30, 2017, and September 30, 2017."}],"balance_after":42500,"source":{"system":"sec-edgar","filing":"0001415889-17-001684","document":"form4-10232017_021051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000141588917001684/form4-10232017_021051.xml","form_type":"4"}},{"id":4181887,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2017-10-23T16:40:23.000Z","date":"2017-10-20","kind":"grant","acquired":true,"shares":425000,"price":0.81,"value":344250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":425000,"derivative":{"exercise_price":0.81,"expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001213900-17-010835","document":"f4101917shenouda_relmada.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390017010835/f4101917shenouda_relmada.xml","form_type":"4"}},{"id":4200943,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Options","published_at":"2017-09-27T21:12:19.000Z","date":"2017-09-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options with respect to 75,000 shares vest upon the acceptance of a US IND for MS 1819, and the remaining 25,000 vest upon the Registrant's completion of a Phase IIa clinical trial for MS1819."}],"balance_after":100000,"derivative":{"exercise_price":4.39,"expiration_date":"2027-09-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-17-001573","document":"form4-09272017_060908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000141588917001573/form4-09272017_060908.xml","form_type":"4"}},{"id":4464147,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2017-02-07T16:39:43.000Z","date":"2017-02-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"10,000 options vest immediately. The balance vests 1/24 per month."}],"balance_after":30000,"derivative":{"exercise_price":4.48,"expiration_date":"2027-02-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-17-000212","document":"form4-02072017_010233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000141588917000212/form4-02072017_010233.xml","form_type":"4"}}]}